-transparent.png){kind=logo}
Ribavirin, when administered intraperitoneally to mice infected with Friend leukemia virus, significantly inhibited development of the disease as determined by inhibition of virus-induced splenomegaly and viable virus titers in the spleen and plasma of the infected animals. The drug was effective whether administered ip in multiple daily treatments, treatments every three days, or single injection. Greatest efficacy was seen when therapy began early in the infection, presumably while the virus was in its eclipse phase.
Related Publications
R W Sidwell, and
L B Allen, and
J H Huffman, and
J T Witkowski, and
L N Sinon
April 1980,
Immunopharmacology,
R W Sidwell, and
L B Allen, and
J H Huffman, and
J T Witkowski, and
L N Sinon
May 1975,
Antimicrobial agents and chemotherapy,
R W Sidwell, and
L B Allen, and
J H Huffman, and
J T Witkowski, and
L N Sinon
June 1979,
Journal of medicinal chemistry,
R W Sidwell, and
L B Allen, and
J H Huffman, and
J T Witkowski, and
L N Sinon
March 1977,
Annals of the New York Academy of Sciences,
R W Sidwell, and
L B Allen, and
J H Huffman, and
J T Witkowski, and
L N Sinon
April 1973,
Antimicrobial agents and chemotherapy,
R W Sidwell, and
L B Allen, and
J H Huffman, and
J T Witkowski, and
L N Sinon
March 1977,
Annals of the New York Academy of Sciences,
R W Sidwell, and
L B Allen, and
J H Huffman, and
J T Witkowski, and
L N Sinon
June 1976,
Journal of medicinal chemistry,
R W Sidwell, and
L B Allen, and
J H Huffman, and
J T Witkowski, and
L N Sinon
August 1976,
The Journal of general virology,
R W Sidwell, and
L B Allen, and
J H Huffman, and
J T Witkowski, and
L N Sinon
June 1977,
Biochemical pharmacology,
R W Sidwell, and
L B Allen, and
J H Huffman, and
J T Witkowski, and
L N Sinon
July 1991,
Biochemical and biophysical research communications,
